Form 4 for PRLD Prelude Therapeutics Inc
Accepted 2025-03-27 00:00:00 ET · period of report 2025-03-25 · accession 0001562180-25-002778 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-27 | 2025-03-25 | PRLD | Vaddi Krishna | CEO, Dir | P - Purchase | $0.69 | +675.0K | 2.00M | +51% | +$465.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-03-25 | P | A | 675,000 | $0.69 | 1,999,296 | D | — | — |